Clinical Trial

Assessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically

Study acronym: PPIX
Recruiting
View on ClinicalTrials.gov →
Summary
The primary objective of this study is the evaluation of the efficacy of the tissue oxygen imager based on PpIX DF in differentiating benign skin growth from non-melanoma skin cancer (NMSC).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-30.
Status change: Not Yet Recruiting → Recruiting 2026-02-04
Trial Details
NCT Number NCT07201376
Lead Sponsor Dartmouth-Hitchcock Medical Center
Collaborators: Dartmouth College
Conditions Non-Melanoma Skin Cancer (NMSC), Benign Skin Growth
Enrollment 125 participants
Start Date 2025-11-14
Primary Completion 2026-11 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-02-06